CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cellectis S.A.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026
$0.93−0.11 (-11.01%)
Close on Oct 19, 2026
- Market cap
- $93.15M
- P/E (TTM)
- –
- Dividend yield
- –
Cellectis S.A. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plants [member] | – | – | – | – | $26.95M | $22.89M | $7.29M | $236.00K | $508.00K | – | – | – |
| Therapeutics [member] | – | – | – | – | $30.35M | $51.06M | $7.90M | $12.50M | $24.68M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| France | $72.95M | $41.51M | $755.00K | $19.17M | $30.35M | $51.06M | $7.90M | $12.50M | $24.68M | $44.41M | 100.0% | +75.8% |
| United States | – | – | $0 | $0 | $0 | $0 | $7.29M | $236.00K | $508.00K | $399.00K | – | – |
| Other European Countries [Member] | – | $0 | $0 | $0 | – | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Cellectis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.